Technical University Munich
Drug Combination, Biomarker Search Continues in Urothelial Cancer After Mixed ESMO Trial Data
Premium
Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.